233 related articles for article (PubMed ID: 21536143)
1. A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change.
Mitchell SA; Jacobsohn D; Thormann Powers KE; Carpenter PA; Flowers ME; Cowen EW; Schubert M; Turner ML; Lee SJ; Martin P; Bishop MR; Baird K; Bolaños-Meade J; Boyd K; Fall-Dickson JM; Gerber LH; Guadagnini JP; Imanguli M; Krumlauf MC; Lawley L; Li L; Reeve BB; Clayton JA; Vogelsang GB; Pavletic SZ
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1619-29. PubMed ID: 21536143
[TBL] [Abstract][Full Text] [Related]
2. Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease.
Cardones AR; Sullivan KM; Green C; Chao NJ; Rowe-Nichols K; Bañez LL; Burton CS; Horwitz ME; Long GD; Rao CL; Sarantopoulos S; Sidhu-Malik N; Sung AD; Hall RP
JAMA Dermatol; 2019 Jul; 155(7):833-837. PubMed ID: 30994873
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease.
Baumrin E; Baker LX; Byrne M; Martin PJ; Flowers ME; Onstad L; El Jurdi N; Chen H; Beeghly-Fadiel A; Lee SJ; Tkaczyk ER
JAMA Dermatol; 2023 Apr; 159(4):393-402. PubMed ID: 36884224
[TBL] [Abstract][Full Text] [Related]
4. Oral chronic graft-versus-host disease scoring using the NIH consensus criteria.
Treister NS; Stevenson K; Kim H; Woo SB; Soiffer R; Cutler C
Biol Blood Marrow Transplant; 2010 Jan; 16(1):108-14. PubMed ID: 19772943
[TBL] [Abstract][Full Text] [Related]
5. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in pediatric patients after allogeneic SCT: development of the PedsQL Stem Cell Transplant module and results of a pilot study.
Lawitschka A; Güclü ED; Varni JW; Putz M; Wolff D; Pavletic S; Greinix H; Peters C; Felder-Puig R
Bone Marrow Transplant; 2014 Aug; 49(8):1093-7. PubMed ID: 24820217
[TBL] [Abstract][Full Text] [Related]
7. National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.
Baird K; Steinberg SM; Grkovic L; Pulanic D; Cowen EW; Mitchell SA; Williams KM; Datiles MB; Bishop R; Bassim CW; Mays JW; Edwards D; Cole K; Avila DN; Taylor T; Urban A; Joe GO; Comis LE; Berger A; Stratton P; Zhang D; Shelhamer JH; Gea-Banacloche JC; Sportes C; Fowler DH; Gress RE; Pavletic SZ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):632-9. PubMed ID: 23340040
[TBL] [Abstract][Full Text] [Related]
8. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.
Cuvelier GDE; Nemecek ER; Wahlstrom JT; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Flower A; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savaşan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; West LJ; Pan B; Al Hamarneh YN; Halevy A; Schultz KR
Blood; 2019 Jul; 134(3):304-316. PubMed ID: 31043425
[TBL] [Abstract][Full Text] [Related]
9. Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium.
Treister N; Chai X; Kurland B; Pavletic S; Weisdorf D; Pidala J; Palmer J; Martin P; Inamoto Y; Arora M; Flowers M; Jacobsohn D; Jagasia M; Arai S; Lee SJ; Cutler C
Bone Marrow Transplant; 2013 Aug; 48(8):1123-8. PubMed ID: 23353804
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
11. Validation of measurement scales in ocular graft-versus-host disease.
Inamoto Y; Chai X; Kurland BF; Cutler C; Flowers ME; Palmer JM; Carpenter PA; Heffernan MJ; Jacobsohn D; Jagasia MH; Pidala J; Khera N; Vogelsang GB; Weisdorf D; Martin PJ; Pavletic SZ; Lee SJ;
Ophthalmology; 2012 Mar; 119(3):487-93. PubMed ID: 22153706
[TBL] [Abstract][Full Text] [Related]
12. Use of the NIH consensus criteria in cellular and soluble biomarker research in chronic graft-versus-host disease: A systematic review.
Milosevic E; Babic A; Iovino L; Markovic M; Grce M; Greinix H
Front Immunol; 2022; 13():1033263. PubMed ID: 36389657
[TBL] [Abstract][Full Text] [Related]
13. A single-center pilot validation study of a new chronic GVHD skin scoring system.
Greinix HT; Pohlreich D; Maalouf J; Soukup P; Supper V; Kalhs P; Knobler RM
Biol Blood Marrow Transplant; 2007 Jun; 13(6):715-23. PubMed ID: 17531782
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of oral chronic graft-versus-host disease according to the 2014 National Institutes of Health (USA) consensus criteria.
Pengpis N; Prueksrisakul T; Chanswangphuwana C
Med Oral Patol Oral Cir Bucal; 2023 Mar; 28(2):e167-e173. PubMed ID: 36173715
[TBL] [Abstract][Full Text] [Related]
15. Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients.
Curtis LM; Pirsl F; Steinberg SM; Mitchell SA; Baird K; Cowen EW; Mays J; Buxbaum NP; Pichard DC; Im A; Avila D; Taylor T; Fowler DH; Gress RE; Pavletic SZ
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1980-1988. PubMed ID: 28797782
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.
Sato T; Ichinohe T; Kanda J; Yamashita K; Kondo T; Ishikawa T; Uchiyama T; Takaori-Kondo A
Int J Hematol; 2011 Apr; 93(4):532-541. PubMed ID: 21465116
[TBL] [Abstract][Full Text] [Related]
17. Validation of the National Institutes of Health (NIH) scale for oral chronic graft-versus-host disease (cGVHD).
Elad S; Zeevi I; Or R; Resnick IB; Dray L; Shapira MY
Biol Blood Marrow Transplant; 2010 Jan; 16(1):62-9. PubMed ID: 19733252
[TBL] [Abstract][Full Text] [Related]
18. NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD.
Curtis LM; Grkovic L; Mitchell SA; Steinberg SM; Cowen EW; Datiles MB; Mays J; Bassim C; Joe G; Comis LE; Berger A; Avila D; Taylor T; Pulanic D; Cole K; Baruffaldi J; Fowler DH; Gress RE; Pavletic SZ
Bone Marrow Transplant; 2014 Dec; 49(12):1513-20. PubMed ID: 25153693
[TBL] [Abstract][Full Text] [Related]
19. Oral disease profiles in chronic graft versus host disease.
Bassim CW; Fassil H; Mays JW; Edwards D; Baird K; Steinberg SM; Cowen EW; Naik H; Datiles M; Stratton P; Gress RE; Pavletic SZ
J Dent Res; 2015 Apr; 94(4):547-54. PubMed ID: 25740857
[TBL] [Abstract][Full Text] [Related]
20. Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures.
Bassim CW; Fassil H; Mays JW; Edwards D; Baird K; Steinberg SM; Williams KM; Cowen EW; Mitchell SA; Cole K; Taylor T; Avila D; Zhang D; Pulanic D; Grkovic L; Fowler D; Gress RE; Pavletic SZ
Bone Marrow Transplant; 2014 Jan; 49(1):116-21. PubMed ID: 23995099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
